Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.32 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25006833 | 0.79 | ALDH1A1 (0.36) | CA1CA2GRIK1GRIK2GRM1 | |
| SCHEMBL10458343 | 0.79 | ALDH1A1 (0.36) | CA1CA2GRIK1GRIK2GRM1 | |
| SCHEMBL21557288 | 0.79 | TDP1 (0.38) | CA1CA2GRIK1GRIA4GRIK3 | |
| Hydrochloric Acid SCHEMBL29414281 | 0.78 | ALDH1A1 (0.36) | CA1CA2GRIK1GRIK2GRM1 | |
| SCHEMBL15451505 | 0.78 | ESRRB (0.36) | CA1CA2SMN1; SMN2ZDHHC7KMT2A | |
| SCHEMBL25660937 | 0.77 | GRIK1 (0.56) | GRIK1GRIK2GRIA4GRIK3GRIK5 | |
| SCHEMBL25660325 | 0.77 | GRIK1 (0.56) | GRIK1GRIK2GRIA4GRIK3GRIK5 | |
| SCHEMBL1427176 | 0.76 | GRIK1 (0.41) | GRIK1GRIK2GRM1GRM2SMN1; SMN2 | |
| SCHEMBL11292145 | 0.76 | ALDH1A1 (0.33) | CA1CA2SMN1; SMN2ZDHHC7KMT2A | |
| SCHEMBL8894673 | 0.75 | SMN1; SMN2 (0.42) | CA1CA2SMN1; SMN2ZDHHC7KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398757-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4380920-A1 | INHIBITORS FOR CORONAVIRUSES | Cocrystal Pharma, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118103351-A | Coronavirus inhibitors | 共晶制药公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023014758-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023014758-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398757-A1 | INHIBITORS FOR CORONAVIRUSES | ACE, ACE2, SARS1 | CA1 1862/4885CA2 1835/4885GRIK1 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.